SPAC Research

News, analysis and commentary on the SPAC market

[SPAC Research @SPACalpha]

Updated #Investor #presentation on (Nasdaq: ALPA) Carmell Therapeutics as filed with the #SEC.

#mergersandacquisitions #regenerativemedicine #orthopedics #aesthetics #alopecia Nasdaq @Ranhubbell Patrick Sturgeon https://t.co/YeFJrPIZW9

[SPAC Research @SPACalpha]

My interview at the Nasdaq on our upcoming #acquisition closing of Carmell Therapeutics

Randy Hubbell Patrick St@Ranhubbell Watkins Niki Dunne Jordan Saxe ⛷️ https://t.co/pLXnKTch4M

[SPAC Research @SPACalpha]

#Performance of #Venture backed #Unicorn #IPOs
Brilliant analysis by #Crunchbase: Let’s say you bought a share of Unicorn startups that launched the largest IPOs in the past 10 years at the market peak in November 2021. Then here is how you would have do…https://t.co/FmO8D6MdIS

[SPAC Research @SPACalpha]

https://t.co/6p83NIla1m

[SPAC Research @SPACalpha]

On St. Patrick’s Day, here is a mighty fine ditty for us to enjoy!

#patricksday #punjabi https://t.co/VCWx2wo6kX

[SPAC Research @SPACalpha]

#SVB issues principally linked to HTM treasuries.

Here is my understanding (I am no bank expert so please don’t rely on it):
1. SVB grew their #loan book massively driven by cheap deposits
2. They were forced to buy T-bills to maintain #capital ratios
3…https://t.co/togTCsrvG6

[SPAC Research @SPACalpha]

Powell indicates potential for higher pace of rate hikes (not just higher rates). Reaction by S&P #futures.

#powell #federalreserve #rates #equities #bonds https://t.co/7zYMN8dJ0l

[SPAC Research @SPACalpha]

SPAC Research is pleased to launch our new home page with more functionality than ever before - look up the:
1. Latest #Deals announced and closed
2. Latest #IPOs filings and #pricings
3. #Calendar of upcoming events
4. Free #YTM calculator
5. SPAC #spons…https://t.co/JOY1MLjMQ6

[SPAC Research @SPACalpha]

1-year T-bills trading higher than before the dot com collapse, before the LTCM/Currency crises, precursor to the GFC et al.

Yield curve is heavily inverted while equity risk premium remains ostrich like unperturbed in the face of high interest rates an…https://t.co/SNBMqIf3XC

[SPAC Research @SPACalpha]

SPAC Research is pleased to announce a major new product release.

(1) Users can create personal #portfolios to track news and calendar events. If you are a #banker or #lawyer, you can track your clients programmatically instead of manually tracking the…https://t.co/UvLeHNI0WZ

[SPAC Research @SPACalpha]

Alpha Healthcare Acquisition Corp. III Announces Merger with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform Company Developing Allogeneic Plasma-based Biomaterials for Bone and Soft Tissue Healing Indications

Inves…https://t.co/O6zWtMRprP https://t.co/C07FfHUBks

[SPAC Research @SPACalpha]

Liquidated SPACs - as good as #gold ?

Unlike #vc / #privateequity / #hedgefunds that earned 1-2% annual management fees despite losing money (a cost borne by their investors), SPAC sponsors generated profits comparable to investing in gold despite failin…https://t.co/BnLs2tKO6f

[SPAC Research @SPACalpha]

SPAC Research Nov #SPAC #IPO Monitor

Click here for free report covering:
1. Trends in SPAC IPO Activity
2. Trends in SPAC IPO terms
3. State of SPAC IPO pipeline
4. Market reception/pricing of new IPOs
5. Sector and geography focus on new IPOs
6. Leadi…https://t.co/jpDdniLXqY

[SPAC Research @SPACalpha]

Non-institutional & Retail #SPAC #shareholding below Q1 2020 levels

Does this suggest that the #SEC's efforts have worked in reducing retail enthusiasm for SPACs?

#enforcement SPAC Research SPAC Association #investing #investments #stocks https://t.co/Hoh34jWVlZ

[SPAC Research @SPACalpha]

SPAC Research is pleased to launch our new Monthly SPAC IPO Monitor.

Please sign up to get a free copy of this report and our other SPAC reports in your email -- https://t.co/VQq0zsiV45

#nasdaq #nyse #ipo #spacs #research https://t.co/lw693S1cLA

[SPAC Research @SPACalpha]

We compared the performance of #IPOs versus #SPACs in calendar year 2022 YTD and found that:
* Total capital raised by new SPAC listings dropped from $128.7 billion to $12.7 billion – a drop of 90%. Whereas IPO proceeds dropped from $107.4 billion to $6.5…https://t.co/9BgX94SwRz

[SPAC Research @SPACalpha]

@ToTheMaxSPAC Thanks, much appreciated!

[SPAC Research @SPACalpha]

Interview with Mondee, Inc. CEO Prasad Gundumogula and ITHAX Acquisition Corp. CEO Orestes Fintiklis!

https://t.co/32u9FJykJa

[SPAC Research @SPACalpha]

@vik_mittal @danprimack Worth checking what % of IPO book was composed of existing insiders vs new outside money. For most biotech IPOs in last 12 months, I would guess more than 90% insider participation. The IPO is more about setting a new mark than new investors.

[SPAC Research @SPACalpha]

Another week of zero #SPAC IPOs
6 new S-1s filed though - 100% were first time teams with <24 months in tenor, high warrant coverage and either overfunded Trusts and/or Rights for yield investors. Since April, there has been only 1 SPAC S-1 filed involving a bulge bracket bank